No Data
Capricor Therapeutics Initiated at Outperform by Oppenheimer
Capricor Therapeutics Initiated at Outperform by Oppenheimer
Capricorn Therapeutics (CAPR.US) was first covered by Oppenheimer, which gave it an superior market rating and a target price of $14.00.
Capricorn Therapeutics (CAPR.US) was first covered by Oppenheimer, which gave it an superior market rating and a target price of $14.00.
Oppenheimer Initiates Coverage On Capricor Therapeutics With Outperform Rating, Announces Price Target of $14
Oppenheimer analyst Leland Gershell initiates coverage on Capricor Therapeutics with a Outperform rating and announces Price Target of $14.
Capricor Therapeutics: A Buy Rating Backed by Financial Stability and Promising DMD Treatment Developments
Expert Ratings For Capricor Therapeutics
During the last three months, 5 analysts shared their evaluations of Capricor Therapeutics (NASDAQ:CAPR), revealing diverse outlooks from bullish to bearish.The table below summarizes their recent rat
Capricor Therapeutics Is Maintained at Buy by Ladenburg Thalmann
Capricor Therapeutics Is Maintained at Buy by Ladenburg Thalmann